ISPOR EXPANDS SCIENTIFIC STAFF BY ADDITION OF CHIEF SCIENCE OFFICER

Published Sep 1, 2015
Princeton, NJ, USA - The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce it is recruiting for a Senior Director & Chief Science Officer, a new position reporting to the Chief Executive Officer & Executive Director.  This position offers an exceptional opportunity to contribute to the continued success of an internationally recognized health economics and outcomes research society. ISPOR’s knowledge products and services include conferences, education, journals, publications, guidelines, and tools used by thousands of global health economists and health care decision makers annually. By focusing on member input and construction of the consensus view of the appropriate path for advancing HEOR science, the successful candidate will develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. The successful candidate will bring to ISPOR extensive experience.  “We look forward to hearing from senior level candidates with deep professional experience, well versed in health economics and outcomes research as well as a passion for ISPOR.  We encourage applications from the global community based on the following position description”, said Nancy Berg, ISPOR CEO & Executive Director. Further details on the position and application details are available at:  ISPOR eJobs Employment Center.

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×